HUE031828T2 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains - Google Patents

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains Download PDF

Info

Publication number
HUE031828T2
HUE031828T2 HUE12729968A HUE12729968A HUE031828T2 HU E031828 T2 HUE031828 T2 HU E031828T2 HU E12729968 A HUE12729968 A HU E12729968A HU E12729968 A HUE12729968 A HU E12729968A HU E031828 T2 HUE031828 T2 HU E031828T2
Authority
HU
Hungary
Prior art keywords
ser
gly
leu
arg
val
Prior art date
Application number
HUE12729968A
Other languages
English (en)
Hungarian (hu)
Inventor
Judith Baumeister
Marie-Paule Lucienne Armanda Bouche
Carlo Boutton
Marie-Ange Buyse
Veerle Snoeck
Stephanie Staelens
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47423024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE031828(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/067132 external-priority patent/WO2012042026A1/en
Priority claimed from PCT/EP2012/061304 external-priority patent/WO2012175400A1/en
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HUE031828T2 publication Critical patent/HUE031828T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
HUE12729968A 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains HUE031828T2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161500464P 2011-06-23 2011-06-23
US201161500360P 2011-06-23 2011-06-23
US201161541368P 2011-09-30 2011-09-30
PCT/EP2011/067132 WO2012042026A1 (en) 2010-09-30 2011-09-30 Biological materials related to c-met
US13/435,567 US8703135B2 (en) 2010-09-30 2012-03-30 Biological materials related to c-Met
PCT/EP2012/061304 WO2012175400A1 (en) 2011-06-23 2012-06-14 Serum albumin binding proteins

Publications (1)

Publication Number Publication Date
HUE031828T2 true HUE031828T2 (en) 2017-08-28

Family

ID=47423024

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12729968A HUE031828T2 (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Country Status (23)

Country Link
US (11) US20180009888A9 (enExample)
EP (1) EP2723769B2 (enExample)
JP (6) JP6258199B2 (enExample)
KR (7) KR102240318B1 (enExample)
CN (5) CN108659120A (enExample)
AU (7) AU2012273929B2 (enExample)
BR (3) BR112013032145B1 (enExample)
CA (3) CA2837998C (enExample)
DK (1) DK2723769T4 (enExample)
ES (1) ES2622006T5 (enExample)
HU (1) HUE031828T2 (enExample)
IL (4) IL250396B (enExample)
IN (1) IN2014CN00373A (enExample)
LT (1) LT2723769T (enExample)
MX (2) MX350074B (enExample)
NZ (1) NZ780183A (enExample)
PH (7) PH12022550309A1 (enExample)
PL (1) PL2723769T5 (enExample)
PT (1) PT2723769T (enExample)
RU (1) RU2700630C2 (enExample)
SG (4) SG10201805064SA (enExample)
WO (1) WO2012175741A2 (enExample)
ZA (1) ZA201309295B (enExample)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP3466972A1 (en) 2011-06-23 2019-04-10 Ablynx NV Serum albumin binding proteins
EP2974737B1 (en) 2011-06-23 2025-10-22 Ablynx N.V. Techniques for predicting, detecting and reducing a specific protein interference in assays involving immunoglobulin single variable domains
DK2723769T4 (da) * 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
EA027160B1 (ru) * 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
JP2015502741A (ja) 2011-11-04 2015-01-29 ノバルティス アーゲー 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014043509A2 (en) * 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
IL295534B2 (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable sites
CA2948945C (en) * 2014-05-16 2023-08-08 Ablynx Nv Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
CA3255406A1 (en) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
WO2016156466A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
JP6929786B2 (ja) 2015-04-02 2021-09-01 アブリンクス エン．ヴェー． 強力な抗ｈｉｖ活性を有する二重特異性ｃｘｃｒ４−ｃｄ４ポリペプチド
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
CN119219778A (zh) 2015-05-13 2024-12-31 埃博灵克斯股份有限公司 基于cd3反应性的t细胞募集多肽
DK3611192T3 (da) 2015-05-13 2025-06-10 Ablynx Nv T-celle-rekrutterende polypeptider baseret på tcr-alfa/beta-reaktivitet
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
CN108350069B (zh) * 2015-10-30 2021-11-12 埃博灵克斯股份有限公司 针对il-23的多肽
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
US10875918B2 (en) 2015-11-12 2020-12-29 Ablynx N.V. P2X7 receptor binders and polypeptides comprising the same
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
US11142569B2 (en) * 2015-11-13 2021-10-12 Ablynx N.V. Serum albumin-binding immunoglobulin variable domains
CA3005488A1 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
KR102220275B1 (ko) 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
MX2018006243A (es) 2015-11-18 2018-11-09 Merck Sharp & Dohme Proteinas de union a pd1/ctla4.
RU2018122255A (ru) 2015-11-27 2019-12-19 Аблинкс Нв Полипептиды, ингибирующие cd40l
AR106949A1 (es) 2015-12-04 2018-03-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CA3029133C (en) * 2016-06-23 2024-04-30 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
JP2020513248A (ja) 2016-10-19 2020-05-14 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響による親和性細胞抽出
CN110177809B (zh) 2016-11-16 2023-11-03 埃博灵克斯股份有限公司 能够结合CD123和TCRα/β的T细胞募集多肽
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
SG11201906264YA (en) 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
EP3571224B1 (en) * 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
EP3602056A1 (en) 2017-03-31 2020-02-05 Ablynx N.V. Improved immunogenicity assays
KR102717656B1 (ko) 2017-05-31 2024-10-14 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드
TW202417517A (zh) 2017-06-02 2024-05-01 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
AU2018277310B2 (en) 2017-06-02 2024-07-11 Ablynx Nv Aggrecan binding immunoglobulins
JP7249961B2 (ja) 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
HRP20241562T1 (hr) 2017-06-02 2025-01-31 Merck Patent Gmbh Adamts vezujući imunoglobulini
KR102625929B1 (ko) 2017-07-19 2024-01-16 브이아이비 브이지더블유 혈청 알부민 결합제
JP6708797B2 (ja) 2017-08-23 2020-06-10 本田技研工業株式会社 鞍乗り型車両のエアバッグ装置
WO2019086548A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
US10785574B2 (en) 2017-12-14 2020-09-22 Flodesign Sonics, Inc. Acoustic transducer driver and controller
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
ES2993989T3 (en) * 2018-07-10 2025-01-15 Regeneron Pharma Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
WO2020221888A1 (en) 2019-04-30 2020-11-05 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
JP7680377B2 (ja) 2019-06-21 2025-05-20 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CN114466864B (zh) 2019-06-21 2024-12-27 索瑞索制药公司 多肽
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
CA3158991A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
IL293554A (en) 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising an immunoglobulin with one variable domain that target tnfa and ox40l
IL293561A (en) 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23
CA3163910A1 (en) 2019-12-09 2021-06-17 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
US20230087785A1 (en) 2020-02-25 2023-03-23 Vib Vzw Leucine-Rich Repeat Kinase 2 Allosteric Modulators
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
BR112023005273A2 (pt) 2020-09-25 2023-04-25 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a il-13 e ox40l
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
EP4259663A1 (en) 2020-12-14 2023-10-18 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
KR20230123495A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
KR20230123497A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
IL303740A (en) 2020-12-18 2023-08-01 Sanofi Sa T cell recruiting polypeptides based on tcr alpha/beta reactivity
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
AU2022216460A1 (en) 2021-02-05 2023-09-21 Universiteit Gent Sarbecovirus binders
EP4294516A1 (en) 2021-02-19 2023-12-27 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
CN113173978B (zh) * 2021-04-22 2024-03-01 温州医科大学 一种对hpv16e6蛋白具有结合亲和力的多肽及其应用
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
WO2023093899A1 (zh) 2021-11-29 2023-06-01 江苏恒瑞医药股份有限公司 经修饰的蛋白或多肽
EP4448783A1 (en) 2021-12-13 2024-10-23 Heraeus Medical GmbH Tests and methods for detecting bacterial infection
TW202342508A (zh) 2021-12-17 2023-11-01 比利時商艾伯霖克斯公司 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
EP4463479A1 (en) 2022-01-12 2024-11-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023164551A1 (en) 2022-02-23 2023-08-31 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
US20250313611A1 (en) 2022-05-18 2025-10-09 Vib Vzw Sarbecovirus spike s2 subunit binders
TW202423482A (zh) 2022-06-08 2024-06-16 美商泰德治療公司 可電離陽離子脂質和脂質奈米顆粒、及其合成方法和用途
WO2023242247A1 (en) 2022-06-14 2023-12-21 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
CN120077065A (zh) 2022-07-27 2025-05-30 阿布林克斯有限公司 与新生儿Fc受体的特定表位结合的多肽
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate
CN120380024A (zh) 2022-12-21 2025-07-25 建新公司 抗pd-1×4-1bb结合蛋白
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
TW202444749A (zh) 2023-01-09 2024-11-16 美商奧迪希治療公司 抗tnfr2抗原結合蛋白及其用途
IL322564A (en) 2023-02-10 2025-10-01 Amunix Pharmaceuticals Inc Prostate-specific membrane antigen (PSMA)-targeting compositions and methods for their preparation and use
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
AU2024234615A1 (en) 2023-03-14 2025-08-21 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
WO2024231447A1 (en) 2023-05-08 2024-11-14 Sanofi Glycosylation of immunoglobulin single variable domains
AR132699A1 (es) 2023-05-17 2025-07-23 Odyssey Therapeutics Inc Anticuerpos de dominio único modificados
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
AU2024308381A1 (en) 2023-06-29 2025-11-20 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
TW202517676A (zh) 2023-07-05 2025-05-01 比利時商艾伯霖克斯公司 用於治療ＩｇＧ相關疾病及病症之改良ＦｃＲｎ拮抗劑
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
CA2056102C (en) 1990-11-26 2003-03-25 Petrus Gerardus Antonius Steenbakkers Method for the production of antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2001002853A2 (en) * 1999-07-05 2001-01-11 K.U. Leuven Research & Development DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
AU2001289930A1 (en) 2000-09-25 2002-04-08 Rega Stichting Vzw Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
EP1360207B1 (en) 2000-12-13 2011-06-22 Bac Ip B.V. Protein arrays of camelid heavy-chain immunoglobulin variable domains
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP2390270A1 (en) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
US20050079574A1 (en) * 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
KR20070117002A (ko) 2003-11-04 2007-12-11 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 고지혈증·고알부민혈증 모델 동물
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
CA2588892A1 (en) 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
WO2006079372A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2949668B1 (en) † 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
BRPI0609797B8 (pt) 2005-05-20 2021-05-25 Ablynx Nv nanocorpos melhorados para o tratamento de desordens mediadas por agregação
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2006129828A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Target substance capturing molecule
US7989219B2 (en) * 2005-05-31 2011-08-02 Canon Kabushiki Kaisha Bispecific capturing molecule
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
EA200801166A1 (ru) 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
JP2009519011A (ja) 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
CA2640066A1 (en) † 2006-01-24 2007-08-02 Roland Beckmann Fusion proteins that contain natural junctions
CN103183738B (zh) 2006-03-30 2014-08-06 诺瓦提斯公司 c-Met抗体的组合物和使用方法
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
WO2008112004A2 (en) * 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2086998B1 (en) 2006-10-11 2011-12-07 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
US20080267949A1 (en) * 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
HUE033960T2 (en) 2006-12-08 2018-01-29 Lexicon Pharmaceuticals Inc Monoclonal Antibodies to ANGPTL3
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
WO2008077945A2 (en) 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
US20110118185A9 (en) 2007-02-21 2011-05-19 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
MX2009012650A (es) 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AR062123A1 (es) * 2007-07-27 2008-10-15 Inst Nac De Tecnologia Agropec Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
AU2008304574A1 (en) 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
CA2709399C (en) * 2007-12-28 2021-01-19 Genentech, Inc. Anti-hedgehog antibodies
BRPI0907648B1 (pt) 2008-01-29 2022-01-11 Institute Of Molecular Biology And Genetics National Academy Of Science Of Ukraine Anticorpo isolado humanizado, usos de um anticorpo, métodos para preparar um anticorpo, para gerar anticorpos imunorreativos com slc34a2 e para triar ou identificar agentes ou compostos que modulam slc34a2, composições, ácido nucleico isolado, e, microorganismo hospedeiro
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
JP6034023B2 (ja) 2008-05-16 2016-11-30 アブリンクス エン．ヴェー． Ｃｘｃｒ４及び他のｇｐｃｒに指向性を有するアミノ酸配列及びそれを含む化合物
US7858729B2 (en) 2008-05-29 2010-12-28 Novomer, Inc. Methods of controlling molecular weight distribution of polymers and compositions thereof
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2010042815A2 (en) * 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
US8372808B2 (en) 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
WO2010100135A1 (en) † 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EA021146B1 (ru) 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
US8450888B2 (en) 2009-04-20 2013-05-28 General Electric Company Integrated brushless starter/generator system
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
HUE051430T2 (hu) * 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
US9644022B2 (en) * 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
HUE029824T2 (en) * 2009-12-18 2017-04-28 Sanofi Sa Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
MX2012005345A (es) 2009-12-23 2012-06-08 Esbatech Alcon Biomed Res Unit Metodo para disminuir inmunogenicidad.
UY33253A (es) 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
EP2563814A1 (en) * 2010-04-30 2013-03-06 Ablynx N.V. Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) † 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
CA2823104A1 (en) * 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
WO2012131053A1 (en) 2011-03-30 2012-10-04 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha
WO2012130314A1 (en) † 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
EP3466972A1 (en) 2011-06-23 2019-04-10 Ablynx NV Serum albumin binding proteins
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PE20141659A1 (es) 2011-07-27 2014-11-21 Glaxo Group Ltd Dominios variables singulares anti-vgf fusionados con dominios de fc
EA027160B1 (ru) 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US8614548B2 (en) 2012-01-19 2013-12-24 Sonoco Development Incorporated Electroluminescent display and method for production
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CN104487239A (zh) 2012-05-22 2015-04-01 欧文斯科宁知识产权资产有限公司 层压泡沫产品和制造层压泡沫产品的方法
WO2014111550A1 (en) † 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
CA2948945C (en) 2014-05-16 2023-08-08 Ablynx Nv Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
IL295534B2 (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable sites
WO2016062766A1 (en) * 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
NO2768984T3 (enExample) 2015-11-12 2018-06-09
US11142569B2 (en) 2015-11-13 2021-10-12 Ablynx N.V. Serum albumin-binding immunoglobulin variable domains
CA3005488A1 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
KR102220275B1 (ko) 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
MX2018006243A (es) 2015-11-18 2018-11-09 Merck Sharp & Dohme Proteinas de union a pd1/ctla4.
WO2017129630A1 (en) * 2016-01-26 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-vwf d'd3 single-domain antibodies and polypeptides comprising thereof
IL310340A (en) * 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
SG11201906264YA (en) * 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
JP7249961B2 (ja) * 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
AU2018277310B2 (en) 2017-06-02 2024-07-11 Ablynx Nv Aggrecan binding immunoglobulins
HRP20241562T1 (hr) * 2017-06-02 2025-01-31 Merck Patent Gmbh Adamts vezujući imunoglobulini
TW202417517A (zh) * 2017-06-02 2024-05-01 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
IL276200B2 (en) * 2018-02-06 2025-01-01 Ablynx Nv Polypeptide comprising two variable domains of anti-human (vWF) immunoglobulins VON- for use in the treatment of a first episode of von Willebrand Factor (vWF)-related disease
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
KR20230123495A (ko) * 2020-12-18 2023-08-23 아블린쓰 엔.브이. 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드

Also Published As

Publication number Publication date
AU2018202782B2 (en) 2020-07-16
IN2014CN00373A (enExample) 2015-04-03
US20210388062A1 (en) 2021-12-16
CA2837998C (en) 2022-03-01
WO2012175741A2 (en) 2012-12-27
AU2017204339B2 (en) 2019-03-28
AU2021201506B2 (en) 2023-10-19
CN108659121A (zh) 2018-10-16
AU2024200309A1 (en) 2024-02-08
CN104203975B (zh) 2018-05-11
PT2723769T (pt) 2017-04-04
IL250396B (en) 2022-06-01
KR20240033183A (ko) 2024-03-12
KR102240318B1 (ko) 2021-04-15
CN108659120A (zh) 2018-10-16
MX2013014614A (es) 2014-08-01
US10858418B2 (en) 2020-12-08
MX2018007826A (es) 2021-12-08
KR102025035B1 (ko) 2019-11-04
CA3141978A1 (en) 2012-12-27
KR102880093B1 (ko) 2025-10-31
PH12022550312A1 (en) 2023-01-23
EP2723769B2 (en) 2022-06-15
US20230242620A1 (en) 2023-08-03
US20210388061A1 (en) 2021-12-16
IL293163A (en) 2022-07-01
EP2723769B1 (en) 2017-01-11
JP2014520134A (ja) 2014-08-21
US20200216532A1 (en) 2020-07-09
BR122018012485B1 (pt) 2022-09-20
AU2019201606A1 (en) 2019-04-04
AU2019201606B2 (en) 2021-04-01
DK2723769T4 (da) 2022-09-05
LT2723769T (lt) 2017-04-10
KR102430693B1 (ko) 2022-08-08
JP2021107426A (ja) 2021-07-29
PL2723769T5 (pl) 2022-10-17
JP6258199B2 (ja) 2018-01-10
SG10201805064SA (en) 2018-07-30
IL293155A (en) 2022-07-01
US20140199295A1 (en) 2014-07-17
BR112013032145A2 (pt) 2017-12-05
NZ716279A (en) 2017-07-28
SG194982A1 (en) 2013-12-30
CN108663504B (zh) 2021-06-22
PH12013502669B1 (en) 2018-08-10
US20170275361A1 (en) 2017-09-28
AU2020230299A1 (en) 2020-10-01
KR101965462B1 (ko) 2019-04-04
KR20220114104A (ko) 2022-08-17
US20180009888A9 (en) 2018-01-11
PL2723769T3 (pl) 2017-07-31
US11192937B2 (en) 2021-12-07
JP6869923B2 (ja) 2021-05-12
JP2022031790A (ja) 2022-02-22
US20220298227A9 (en) 2022-09-22
BR122017005075A2 (pt) 2019-09-03
CN108653728B (zh) 2022-11-18
US11192938B2 (en) 2021-12-07
WO2012175741A3 (en) 2013-02-14
AU2018202782A1 (en) 2018-05-10
BR122017005075B1 (pt) 2022-09-20
CN104203975A (zh) 2014-12-10
AU2017204339A1 (en) 2017-07-13
NZ617995A (en) 2016-06-24
ES2622006T5 (es) 2022-10-13
CA2837998A1 (en) 2012-12-27
NZ780183A (en) 2024-12-20
CN108663504A (zh) 2018-10-16
SG10201605048XA (en) 2016-07-28
US12006352B2 (en) 2024-06-11
RU2700630C2 (ru) 2019-09-18
KR20210047369A (ko) 2021-04-29
US20180355031A1 (en) 2018-12-13
US20210403536A1 (en) 2021-12-30
RU2019128430A (ru) 2019-10-25
KR20190107200A (ko) 2019-09-18
KR20190041513A (ko) 2019-04-22
KR20180086280A (ko) 2018-07-30
AU2020230299B2 (en) 2022-10-06
PH12022550309A1 (en) 2023-01-23
US20220119497A1 (en) 2022-04-21
IL229503B (en) 2022-06-01
PH12022550310A1 (en) 2023-01-23
BR112013032145B1 (pt) 2022-09-20
US20200325221A1 (en) 2020-10-15
CN108653728A (zh) 2018-10-16
ZA201309295B (en) 2015-01-28
PH12013502669A1 (en) 2014-02-10
PH12022550311A1 (en) 2023-01-23
RU2014102007A (ru) 2015-11-27
BR112013032145A8 (pt) 2018-07-03
KR20140040779A (ko) 2014-04-03
ES2622006T3 (es) 2017-07-05
IL229503A0 (en) 2014-01-30
DK2723769T3 (en) 2017-04-03
MX350074B (es) 2017-08-25
JP2018162305A (ja) 2018-10-18
CA3142288A1 (en) 2012-12-27
PH12022550313A1 (en) 2023-01-23
KR102246924B1 (ko) 2021-04-30
AU2021201506A1 (en) 2021-03-25
PH12017501178A1 (en) 2018-07-23
EP2723769A2 (en) 2014-04-30
IL250396A0 (en) 2017-03-30
US20170275360A1 (en) 2017-09-28
JP2017160230A (ja) 2017-09-14
JP6982400B2 (ja) 2021-12-17
JP2024050769A (ja) 2024-04-10
AU2012273929B2 (en) 2017-04-27
SG10201707604SA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
AU2021201506B2 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US11644471B2 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2974737B1 (en) Techniques for predicting, detecting and reducing a specific protein interference in assays involving immunoglobulin single variable domains
US20150344568A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
HK1260064A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
EP4350345A2 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
HK1260347A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
NZ617995B2 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NZ716279B2 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains